Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

‘Intended Use’ Rule: Industry Urges US FDA To Revoke ‘Totality Of Evidence’ Standard

Executive Summary

Trade groups say final rule would allow any activity to be considered evidence of a manufacturer’s intended use of a product and increase exposure to potential liability.

Advertisement

Related Content

'Intended Use' Rule: US FDA May Toss Its 'Totality Of Evidence' Standard
Biopharma Wins Reprieve On US FDA 'Intended Use' Rule
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Judge Gorsuch Could Be Pharma Ally In FDA Disputes
First Amendment Does Not Block Off-Label Enforcement Actions, FDA Reiterates
US FDA Clarifies ‘Intended Use’ Policy For Approved Products

Topics

Advertisement
UsernamePublicRestriction

Register

PS120031

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel